GSK: tightens guidance after quarterly earnings rise
(CercleFinance.com) - GlaxoSmithKline reported higher quarterly earnings on Wednesday as strong sales of vaccines and pharmaceuticals helped to offset more muted trading at its consumer healthcare unit.
The drugmaker's Q3 sales rose by 3% to 8.1 billion pounds, with adjusted operating profit up 2% at 2.5 billion pounds, helped by cost control.
CEO Emma Walmsley said that GSK has made "further good progress" over the past quarter, citing "strong commercial execution" for key products and new launches, such as the shingles vaccine, Shingrix.
Glaxo has tightened its full-year guidance range towards the upper end of previous expectations, now expecting 2018 adjusted EPS growth of 8-10% at constant exchange rates.
The London-listed shares of GlaxoSmithKline were up 2.5% following this news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drugmaker's Q3 sales rose by 3% to 8.1 billion pounds, with adjusted operating profit up 2% at 2.5 billion pounds, helped by cost control.
CEO Emma Walmsley said that GSK has made "further good progress" over the past quarter, citing "strong commercial execution" for key products and new launches, such as the shingles vaccine, Shingrix.
Glaxo has tightened its full-year guidance range towards the upper end of previous expectations, now expecting 2018 adjusted EPS growth of 8-10% at constant exchange rates.
The London-listed shares of GlaxoSmithKline were up 2.5% following this news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.